Skip to main content
Go to the home page of the European Commission (opens in new window)
English en
CORDIS - EU research results
CORDIS

Management of chronic cardiometabolic disease and treatment discontinuity in adult ADHD patients

Project description

Managing ADHD and cardiometabolic diseases

The EU-funded TIMESPAN project aims to advance the management of patients with attention deficit hyperactivity disorder (ADHD) and co-occurring cardiometabolic disease by improving available treatments and risk stratification. The two conditions share substantial comorbidity and common genetics, with cardiometabolic disease leading to premature deaths and placing a substantial burden on healthcare systems. Moreover, the co-existence of psychiatric disorders in patients with this profile cannot be overlooked. The project's work is expected to improve the clinical outcomes as well as the quality of life of adult ADHD patients with co-occurring cardiometabolic disease.

Objective

TIMESPAN's main objective is to advance the management of patients with Attention Deficit Hyperactivity Disorders (ADHD) and co-occurring cardiometabolic disease by improving available treatments and risk stratification. Emerging evidence points at substantial comorbidity and shared genetics between adult ADHD and cardiometabolic diseases (i.e. Obesity, Type-2 Diabetes and cardiovascular disease). Inadequate treatment of cardiometabolic disease is strongly associated with premature death and substantial societal costs. National guidelines of cardiometabolic disease have stressed the importance of co-occurring psychiatric disorders. However, even though ADHD is a common (prevalence ≈2 to 5% in adults) and serious complex chronic condition, knowledge about appropriate management of adults with ADHD and co-occurring cardiometabolic disease is lacking. We will address the main objective using existing large-scale cohort studies and linked electronic health record databases in multiple countries with different health care systems. We also use smartphones and wearable devices to obtain novel real-time and multi-parametric measurements of ADHD medication treatment and cardiometabolic risks. The combined use of unparalleled data sources and new technologies for data collection, management, analytics will identify optimized and personalized multidisciplinary treatment approaches that minimise harm and maximise positive changes in disease prognosis and improve treatment discontinuity. TIMESPAN is expected to improve the clinical outcomes, as well as quality of life in adult ADHD patients with co-occurring cardiometabolic disease and also to also facilitates developments of new technological tools for advanced data management, monitoring and analytics for European stakeholders. TIMESPAN strategies to inform clinicians, patients, health authorities, and general public allow for a sustainable implementation of our findings (e.g. recommendations for treatment guidelines).

Keywords

Programme(s)

Topic(s)

Funding Scheme

RIA - Research and Innovation action

See all projects funded under this funding scheme

Call for proposal

(opens in new window) H2020-SC1-BHC-2018-2020

See all projects funded under this call

Coordinator

OREBRO UNIVERSITY
Net EU contribution
€ 366 750,00
Address
FAKULTETSGATAN 1
70182 Orebro
Sweden
Region
Östra Sverige Östra Mellansverige Örebro län
Activity type
Higher or Secondary Education Establishments
Links
Total cost
€ 366 750,00

Participants (16)